1.Is a Confirmed Case of Mild COVID-19 infection (defined as per ICMR guidelines) without evidence of breathlessness or Hypoxia (normal saturation). <br/ >2.Is a Confirmed Case of Severe COVID-19 infection (defined as per ICMR guidelines) exhibiting the following signs & symptoms: <br/ > a)SpO2: <90% (on room air). <br/ > b)Respiratory Rate: > 30/ minute, <br/ > c)Chest imaging shows (Chest X ray and portable bed side lung ultrasound): <br/ > bilateral opacities, not fully explained by effusions, lobar or lung <br/ > collapse, or nodules. <br/ >3.Testing positive for HIV, HbsAg and HCV infection. <br/ >4.Females who are currently pregnant or breastfeeding. <br/ >5.Has a known allergy or other contraindication to Eflornithine. <br/ >6.Has received Eflornithine within the last 10 days. <br/ >7.Has received anti-viral or anti-malarial or anti-bacterial within the last 14 days. <br/ >8.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN). <br/ >9.QTc interval â?¥ 500ms. <br/ >10.Recent Myocardial Infarction (within last 6 months). <br/ >11.Known case of (K/C/O) Congestive heart failure. <br/ >12.K/C/O Chronic Kidney Disease. <br/ >13.K/C/O of epilepsy. <br/ >14.K/C/O active Tuberculosis. <br/ >15.In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. <br/ >16.The patient has participated in other clinical trials in the last three months. <br/ >17.Anticipated transfer to another hospital which is not a study site within 72 hours. <br/ >

1.Is a Confirmed Case of Mild COVID-19 infection (defined as per ICMR guidelines) without evidence of breathlessness or Hypoxia (normal saturation). <br/ >2.Is a Confirmed Case of Severe COVID-19 infection (defined as per ICMR guidelines) exhibiting the following signs & symptoms: <br/ > a)SpO2: <90% (on room air). <br/ > b)Respiratory Rate: > 30/ minute, <br/ > c)Chest imaging shows (Chest X ray and portable bed side lung ultrasound): <br/ > bilateral opacities, not fully explained by effusions, lobar or lung <br/ > collapse, or nodules. <br/ >3.Testing positive for HIV, HbsAg and HCV infection. <br/ >4.Females who are currently pregnant or breastfeeding. <br/ >5.Has a known allergy or other contraindication to Eflornithine. <br/ >6.Has received Eflornithine within the last 10 days. <br/ >7.Has received anti-viral or anti-malarial or anti-bacterial within the last 14 days. <br/ >8.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN). <br/ >9.QTc interval â?¥ 500ms. <br/ >10.Recent Myocardial Infarction (within last 6 months). <br/ >11.Known case of (K/C/O) Congestive heart failure. <br/ >12.K/C/O Chronic Kidney Disease. <br/ >13.K/C/O of epilepsy. <br/ >14.K/C/O active Tuberculosis. <br/ >15.In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. <br/ >16.The patient has participated in other clinical trials in the last three months. <br/ >17.Anticipated transfer to another hospital which is not a study site within 72 hours. <br/ >

N/A

N/A

1.Is a Confirmed Case of Mild COVID-19 infection (defined as per ICMR guidelines) without evidence of breathlessness or Hypoxia (normal saturation). <br/ >2.Is a Confirmed Case of Severe COVID-19 infection (defined as per ICMR guidelines) exhibiting the following signs & symptoms: <br/ > a)SpO2: <90% (on room air). <br/ > b)Respiratory Rate: > 30/ minute, <br/ > c)Chest imaging shows (Chest X ray and portable bed side lung ultrasound): <br/ > bilateral opacities, not fully explained by effusions, lobar or lung <br/ > collapse, or nodules. <br/ >3.Testing positive for HIV, HbsAg and HCV infection. <br/ >4.Females who are currently pregnant or breastfeeding. <br/ >5.Has a known allergy or other contraindication to Eflornithine. <br/ >6.Has received Eflornithine within the last 10 days. <br/ >7.Has received anti-viral or anti-malarial or anti-bacterial within the last 14 days. <br/ >8.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN). <br/ >9.QTc interval â?¥ 500ms. <br/ >10.Recent Myocardial Infarction (within last 6 months). <br/ >11.Known case of (K/C/O) Congestive heart failure. <br/ >12.K/C/O Chronic Kidney Disease. <br/ >13.K/C/O of epilepsy. <br/ >14.K/C/O active Tuberculosis. <br/ >15.In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. <br/ >16.The patient has participated in other clinical trials in the last three months. <br/ >17.Anticipated transfer to another hospital which is not a study site within 72 hours. <br/ >

1.Is a Confirmed Case of Mild COVID-19 infection (defined as per ICMR guidelines) without evidence of breathlessness or Hypoxia (normal saturation). <br/ >2.Is a Confirmed Case of Severe COVID-19 infection (defined as per ICMR guidelines) exhibiting the following signs & symptoms: <br/ > a)SpO2: <90% (on room air). <br/ > b)Respiratory Rate: > 30/ minute, <br/ > c)Chest imaging shows (Chest X ray and portable bed side lung ultrasound): <br/ > bilateral opacities, not fully explained by effusions, lobar or lung <br/ > collapse, or nodules. <br/ >3.Testing positive for HIV, HbsAg and HCV infection. <br/ >4.Females who are currently pregnant or breastfeeding. <br/ >5.Has a known allergy or other contraindication to Eflornithine. <br/ >6.Has received Eflornithine within the last 10 days. <br/ >7.Has received anti-viral or anti-malarial or anti-bacterial within the last 14 days. <br/ >8.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN). <br/ >9.QTc interval â?¥ 500ms. <br/ >10.Recent Myocardial Infarction (within last 6 months). <br/ >11.Known case of (K/C/O) Congestive heart failure. <br/ >12.K/C/O Chronic Kidney Disease. <br/ >13.K/C/O of epilepsy. <br/ >14.K/C/O active Tuberculosis. <br/ >15.In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. <br/ >16.The patient has participated in other clinical trials in the last three months. <br/ >17.Anticipated transfer to another hospital which is not a study site within 72 hours. <br/ >